ESMO

  ESMO Oncology Weekly Digest — 8–15 February 2026 Key Takeaways •           ESMO Oesophageal CPG Interim Update confirms perioperative FLOT as the preferred standard over neoadjuvant chemoradiotherapy (CROSS) for locally advanced oesophageal/OGJ adenocarcinoma, based on the phase III ESOPEC trial (mOS 66 vs 37 months; HR 0.70). Tislelizumab–ChT added for first-line advanced oesophageal SCC.[1][2] •          …